First-Line Tagraxofusp in BPDCN

The program was sponsored by Menarini Stemline. The content was independently created by OncLive

Rapid Readouts

Rapid Readouts is a video program featuring leading experts who provide in-depth reviews of the most pivotal and practice-changing data that have been unveiled at recent medical oncology conferences. In each video, top oncologists in their specialty present slides and posters from these annual symposiums and meetings, while highlighting the ever-changing landscape of treatment choices for patient management.

Naveen Pemmaraju, MD, reviews subgroup analyses of tagraxofusp as first-line therapy in BPDCN, highlighting durable responses and successful transplant bridging across age and fitness groups

First-Line Tagraxofusp in BPDCN: Subgroup Analyses by Age and Fitness